Elcelyx Therapeutics

Elcelyx was founded in 2010 with venture capital backing based on Gut Sensory Modulation (GSM) technology. Elcelyx’s proprietary, first-in-class Gut Sensory Modulators are delivered directly to the lower gut where they act on molecular targets to elicit physiological and pharmacological effects. The Elcelyx proprietary product candidate, NewMet for Type 2 diabetes is entering Phase 2b development and is a blockbuster opportunity designed to address the unmet needs in the oral anti-diabetic market. Elcelyx is led by an experienced management team and Board of Directors with track records of success in drug development and commercialization. Premier investors along with seasoned scientists and clinicians support the team. In September 2013, Elcelyx announced the formation of NaZura BioHealth Inc, a separate company established to focus on the development on non-NewMet assets. Elcelyx is headquartered in San Diego, California.
Company growth
Type
Private
HQ
San Diego, US
Founded
2010
Size (employees)
16 (est)
Elcelyx Therapeutics was founded in 2010 and is headquartered in San Diego, US

Key People at Elcelyx Therapeutics

Alain D. Baron

Alain D. Baron

President and CEO
Martin R. Brown

Martin R. Brown

Chief Business Officer

Elcelyx Therapeutics Office Locations

Elcelyx Therapeutics has office in San Diego
San Diego, US

Elcelyx Therapeutics Metrics

Elcelyx Therapeutics Summary

Founding Date

2010

Total Funding

$96.8 M

Latest funding size

$40 M

Time since last funding

over 1 year

Investors

We estimate that Elcelyx Therapeutics's latest funding round in October 2015 was $40 M. In total, Elcelyx Therapeutics has raised $96.8 M
We estimate that Elcelyx Therapeutics's current employees are approximately 35% female and 65% male.

Elcelyx Therapeutics Online Presence

Elcelyx Therapeutics Company Life

You may also be interested in